REG - Trellus Health PLC - Notice of Results

Trellus HealthAnnouncement

14/09/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230914:nRSN3715Ma&default-theme=true

RNS Number : 3715M  Trellus Health PLC  14 September 2023

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Notice of Results

Investor Presentation

 

LONDON, U.K. AND NEW YORK, U.S. (14 September 2023). Trellus Health plc (AIM:
TRLS), which is commercializing a scientifically validated and clinically
proven personalized resilience-driven self-management solution for chronic
health conditions at their intersection with mental health, announces that it
expects to report its interim results for the period ended 30 June 2023 on 28
September 2023.

 

Investor Presentation

 

Dr. Marla Dubinsky, CEO and Co-Founder, and Joy Bessenger, Chief Financial
Officer, will provide a live presentation relating to the interim
results via Investor Meet Company on 2 October 2023 at 17:00 BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Trellus Health plc via:

https://www.investormeetcompany.com/trellus-health-plc/register-investor
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.investormeetcompany.com_trellus-2Dhealth-2Dplc_register-2Dinvestor&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=WovxkIrimZbJDsUY12yOjDzcN9uTu1TmGAhgw0TiZCY&m=u2s_HwtDZpJMmMQPlRU1EP0Zrlad12xhdkQuB9yIHwg&s=JyITwz-8wuTjjFZP5xalEdxGH7mXtK1Ak16pYVSQsAI&e=)

 

Investors who already follow Trellus Health plc on the Investor Meet Company
platform will automatically be invited.

 

For further information please contact:

 

 Trellus Health plc                                                          https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, CEO and Co-Founder                                      Via Walbrook PR
 Dr. Daniel Mahony Chairman

 Singer Capital Markets (Nominated Adviser and Broker)                       Tel: +44 (0)20 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR                                  Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                              (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen / Phillip Marriage  Mob: +44 (0)7980 541 893 / 07748 651 727 / 07867 984 082

 

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is the first resilience-focused digital health
company targeting the intersection of chronic illness and mental health.
Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate™, a whole-person technology-enhanced experience that
empowers individuals to master their health and results in relieving disease
burden, building self-management skills and promoting positive health
behaviours that improves outcomes and enables thriving in the face of a
chronic condition.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both experts at treating and healing both the physical
and emotional impacts of IBD and IBS and have been innovators for whole person
healthcare for a combined 50 years.

 

The Company was initially focused on inflammatory bowel disease ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis but has now added Irritable Bowel Syndrome ("IBS"). Given the common
emotional and mental health struggles often experienced by individuals
suffering from a variety of chronic conditions, Trellus Health considers its
approach to have potential utility and demand across many conditions.

 

The Trellus Elevate™ program incorporates the GRITT™ methodology and
learnings on resilience from clinical research and practice conducted at the
Mount Sinai IBD Center for more than five years. This proprietary,
resilience-driven methodology has been scientifically validated to demonstrate
meaningful improvements in patient outcomes, 71% reduction in Emergency
Department (A&E) visits, and 94% reduction in unplanned hospitalisations,
which the directors of the Company believe indicates the potential for
significant cost savings for healthcare payers. Patients with IBD managed with
the proprietary resilience methodology also experienced a 49% reduction in
required opioid use and a 73% reduction in corticosteroid use 12 months
following starting the program which is a major indicator of improved health
outcomes(1).

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

(1) Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) )

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORQXLFFXKLEBBZ